ADVANCED SOLID TUMOR

This study tested a drug called erdafitinib in 316 adults and children with advanced solid tumors that have certain changes in FGFR genes. The main goal was to see if the drug could shrink tumors. Participants had already tried at least one other treatment. The study is now compl…

This study tested whether combining several immunotherapy drugs could help people with advanced prostate cancer that no longer responds to hormone therapy. 59 adults received different combinations of a vaccine and other immune-boosting drugs. The goal was to see if these combina…

This early-phase study tested a new drug called PM14 in 126 people with advanced solid tumors that had not responded to standard treatments. The main goals were to find the safest dose and to see if the drug could shrink tumors or slow their growth. The study is now complete, and…

This early-phase study tested a new drug called BAT1308 in 59 adults with advanced solid tumors that did not respond to standard treatments. The main goal was to find the highest safe dose and check for side effects. Researchers also looked at how the drug moves through the body.…

This study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers (like lymphoma and leukemia) or advanced solid tumors. The main goals were to find safe doses and check for side effects. The trial was completed, but…

This early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in 135 people with advanced solid tumors that have a specific SMARCA4 gene mutation. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. The s…

This study tested a new drug called JAB-21822, taken as a pill, in 29 adults with advanced solid tumors (like lung or colon cancer) that have a specific KRAS G12C mutation. The goal was to see if the drug is safe and can shrink tumors. Participants had already tried at least one …

This early-stage study tested a new drug called HMBD-002, alone or with another drug (pembrolizumab), in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, …

This early-phase study tested a new drug, BR101, in 15 adults with advanced solid tumors that could not be removed by surgery or had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the …

This study tested a new drug called HX009 in 20 adults with advanced solid tumors that had not responded to standard treatments. HX009 is a bifunctional antibody designed to help the immune system attack cancer cells. The main goal was to see if the drug could shrink tumors, and …

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, kidney, or colorectal cancer. The main goal was to find the safest dose …

This study tested a new drug called TJ004309, alone or with another drug (Toripalimab), in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest and most effective dose, and to check for side effects and early si…

This early-stage study tested a new drug called BMS-986315, given alone or with other cancer drugs (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right dose. The study …

This early-phase study tested a new drug called CHS-388 in 145 people with advanced solid tumors (including kidney, liver, and lung cancers) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cance…

This early-stage study tested a treatment made from a patient's own tumor-fighting immune cells, called tumor-infiltrating lymphocytes (TILs). It included 43 adults with advanced solid tumors like melanoma, cervical cancer, and lung cancer. The goal was to find the safest dose an…

This early-phase study tested a new drug called BAT4706 in 28 people with advanced solid tumors (including melanoma) who had no other good treatment options. The main goal was to check the drug's safety and find the best dose for future studies. This is not a cure, but a step tow…

This early-phase trial tested an experimental drug called NB003 in 258 adults with advanced solid tumors, including a type of stomach cancer called GIST. The main goals were to check the drug's safety and find the right dose. The study was open-label, meaning everyone knew they w…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (stomach cancer, liver cancer, or other types) that had stopped responding to standard treatments. The drug was given by IV every two weeks for up to 12 doses, with the option to continue if pa…

This early-phase study tested a new drug (BGB-A445) alone and with another drug (tislelizumab) in 204 people with advanced solid tumors like lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. This is not a cure, but aims t…

This early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This early-phase study tested a new drug called HBM1020 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. The study did not aim to cure the cancer, but to see if the dr…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (like breast or prostate cancer) that had spread. The main goal was to check safety and find the right dose, not to cure the cancer. Participants took a single dose and were monitored…

This study tested a combination of two drugs, durvalumab (an immunotherapy) and tazemetostat (an epigenetic therapy), in 164 adults with advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The goal was to see if the combo could shrink or stabilize tumors. …

This study tested a new oral drug called RP-3500 (camonsertib) alone or combined with talazoparib or gemcitabine in 276 adults with advanced solid tumors that have certain gene mutations. The main goals were to find the safest dose and check for side effects. The study also looke…

This early-phase trial tested the safety and best dose of combining the diabetes drug pioglitazone with the chemotherapy carboplatin in 14 people with advanced or metastatic solid tumors that could not be cured with standard treatments. The goal was to find the maximum tolerated …

This study tested a new drug called LM-108, alone or with an anti-PD-1 antibody, in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Early results focus on controlling tumor growt…

This study tested an experimental drug called LM-302 in 153 adults with advanced solid tumors that have a specific protein (CLDN18.2). The goal was to find a safe dose and see if the drug can shrink tumors. Participants received the drug intravenously, and researchers monitored s…

This study tested a special training program to help people with advanced cancer manage pain and keep doing daily activities. 211 patients took part, learning skills to cope with pain and find meaning despite their illness. The program focused on improving quality of life and red…

This study looked at whether adding a simple blood test (liquid biopsy) to the standard tissue test could help find more gene changes (EGFR mutations) in people with advanced lung cancer. Over 500 patients who had not yet been treated provided both blood and tissue samples. The g…

This study looked at how bosentan, a drug that affects liver enzymes, changes the way the body processes the cancer drug lurbinectedin. It involved 11 adults with advanced solid tumors who had no other treatment options. The goal was to measure drug levels in the blood to underst…